This nonmyeloablative protocol is growing in popularity as patients tolerate it better. In addition, careful adjustment of immunosuppressive agents post-HSCT allows the donor T cells to destroy ...

Allo-SCT also remains the recommended postremission therapy, though similarly preferred in the context of a clinical trial when available, particularly for those undergoing nonmyeloablative ...

A powerful example of this is autologous nonmyeloablative hematopoietic stem cell transplantation combined with immunosuppression, which achieves high rates of remission from T1D. [9] However ...

McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Cancer ...

The safety and efficacy of nonmyeloablative allogeneic stem-cell transplantation also continue to improve, probably offering the greatest hope of cure. One thing is certain: the ground continues ...